1. (Amended) A compound having a structure that
corresponds to the formula:

wherein

R₁, R₂, R₃ and R₄ are the same or different and are individually selected from the group consisting of hydrogen, lower alkyl, lower alkoxy, phenyl, halo, hydroxy, lower alkylsulfonyl, lower alkylthio, nitro, trifluoromethyl, omega-trifluoromethyl lower alkoxy, amino, acetamido, carboxy, alkylhydroxamic acid or where R₁R₂ or R₃R₄, taken , together with the phenyl group to which they are attached, form a naphthyl or substituted naphthyl group wherein the substituent is selected from halo, trifluoromethyl, lower alkyl and lower alkoxy;

R is a straight chained, saturated or unsaturated hydrocarbon that contains 2-16 carbon atoms:

Y is hydrogen, bromo, chloro or lower alkyl; and X is selected from the group consisting of [carboxy,] hydroxy,[acetoxy,] alkanoyloxy having 1-6 carbon atoms, lower alkoxy, lower alkyl carbonyl, oximino, cyano, amino, $[C(O)-R_5]$ and $-C(O)C(O)-R_5$ wherein R_5 is selected from the group consisting of hydrogen, alkyl, lower alkoxy, NR_6R_7 wherein R_6 and R_7 are the same or different and are selected from the group consisting of [hydrogen and lower alkyl, or R_6 or R_7 are selected from the group consisting

of] [hydrogen.] lower alkyl. lower alkoxy, hydroxy, [acyloxy.] lower alkanoyloxy having 1-6 carbon atoms, benzyloxy, 2-hydroxy lower alkyl, [lower alkyl carboxy.] carboxy lower alkyl. phenyl, substituted phenyl, wherein the substituent is selected from halo, trifluoromethyl, lower alkyl and lower alkoxy, pyridyl, thiazolyl, dihydroth azolyl, 5-tetrazolyl, -OCO(CH₂)_nCOR_q wherein R_q is -OH. ONa. dialkylamino such as diethylamino and morpholino, and n is 2 or 3; -OCOR10 wherein R_{10} is $-CH_2NR_{11}R_{12}$ wherein R_{11} and R_{12} are lower alkyl. [such as methy], [cycloalkyl such as] cyclohexyl. or together are [a heterocyclic ring such as] N-methylpiperazino, -OCOR_{1d} wherein R₁₀ is -CH₂Cl, -CH₂O-loweralkyl or \underline{t} -buty. -CH-loweralkyl-CO₂-lower alkyl, -CH₂CH₂NC₂H₅, [acyl such as] acetyl, propionyl or butyryl; -NR₈OH wherein R₈ As hydrogen, -CO-loweralkyl, -CO- \underline{t} -butyl, -COC₇H₁₅, -CO-phenyl, -SO₂-lower alkyl, $-COCO_2$ -lower alkyl, and -COCONHOH; $-NHR_{13}$ wherein R_{13} is hydrogen, -CO-lower alkyl -CO-t-butyl, COC7H15. -CO-phenyl, -SO₂-lower alkyl, -COCO₂-lower alkyl, -COCONHOH, -COCO₂H, COCON lower alkyl)OH, and PO(0-lower alkyl)₂: $-C(R_{14})=NNH-2-th$ azolino, $-CH(OH)R_{14}$ and $-C(O)R_{14}$ wherein R_{14} is hydrogen, [lower alkyl.] phenyl and <u>t</u>-butyl; $-C(=NOH)NH_2$ and -C(=NH)N(OH)-lower alkyl. [W-alkanoate] and O-NR₈R₉ wherein R₈ and R₉ are the same or different and are selected from the group consisting of hydrogen, lower alkyl, phenyl and substituted phenyl wherein the substituent is selected from halo, trifluoro methyl, lower alkyl and lower alkoxy;

with the provisos that:

(a) when Y is brome or chlore, X is -COOH, -CH₂OH or -C(O)-R₅ wherein R₅ is NR₆R₇ and R₆ is OH and R₇ is lower alkyl:

(and)

Some?

(b) at least one of R_1 and R_2 is other than hydrogen where [(i) R-X is (CH₂)₂CO₂H or (CH₂)₂C(O)NHOH, and (ii)] R_3 and R_4 are 4-methoxy, 3-methoxy-4-hydroxy, 2-hydroxy and hydrogen and

(c) at least one of \mathbb{R}_1 and \mathbb{R}_2 , or of \mathbb{R}_3 and \mathbb{R}_4 is other than hydrogen where R-X together contains three saturated carbon atoms linked together by carbon-carbon bonds; and pharmaceutically acceptable salts thereof.

8

4. (Amended) The compound according to claim 3 wherein X is selected from the group consisting of hydroxy, [carboxy.] [a carboxylate salt of a pharmaceutically acceptable cation.] $C(O)-NR_6R_7$ wherein R_6 and R_7 are selected from the group consisting of [hydrogen.] hydroxyl, methyl, \underline{t} -butyl, 2-hydroxyethyl and carboxymethyl.

19. (Amended) A pharmaceutical composition for the alleviation of inflammatory and cardiovascular disorders in mammals for topical, oral, parenteral and aerosol administration, comprising an effective amount of a substituted pyrazole compound [according to claim 1] as in any of claims 7, 9-12 or 15-18 as active ingredient dispersed in a pharmaceutically acceptable carrier.

July >

23. (Amended) A method for treating myocardial insufficiencies, including angina, vasospasm, infarction, comprising administering to said mammal a pharmaceutical composition comprising an amount effective against myocardial insufficiency, of a substituted pyrazole compound [according to claim 1] as in any of claims 7, 9-12 or 15-18 as active ingredient dispersed in a pharmaceutically acceptable carrier.

Claim 9, line 1; delete "of claim 1".

Claim 10. line 1. delete "claim 1" and substitute therefor --claim 7--.

ORTH 518

Claim 11. line 1. delete "claim 1" and substitute therefor --claim 7--.

Claim 12, line 1, delete "claim 1" and substitute therefor --claim 7--.

Claim 15, line 1, delete "of claim 1".

Claim 16, line 1, delete "of claim 1".

Claim 17, line 1, delete "of claim 1".

line 2, delete

"N-carboxymethy1-3-[5-(4-chloropheny1)-"


line 3, delete

"1-(4-methoxyphenyl)-3-pyrazolyl] propanamide."

Cancel claims 6, 8, 13, 14 and 25 without prejudice.

Add the following claim.

AT. A compound having a structure that corresponds to the formula:





wherein

 R_1 and R_3 are selected from the group consisting of halo, trifluoromethyl and methyl and X is selected from the group consisting of $-C(O)-R_5$ wherein R_5 is selected from the group consisting of $-N(CH_3)OH$, $-N(\underline{t}-butyl)OH$, $-N(\underline{i}-propyl)OH$, -N(cyclohexyl)OH, -N(ethyl)OH and -N(phenyl)OH or R_5 is $-NHCH_2CO_2H$, or X is $-CH_2NH_2$, -C(O)H or -C(=NOH)H.